brd4-b Antibody

What is the molecular function of BRD4 that makes it an important antibody target?

BRD4 functions primarily as an epigenetic reader that specifically recognizes acetylated lysine residues on histones. It belongs to the bromodomain and extraterminal (BET) protein family and acts as a general regulator for RNA polymerase II-dependent transcription through interaction with P-TEFb. Genomic landscape analysis has revealed that BRD4 associates with essentially all active promoters and a significant proportion of active enhancers across various normal and transformed cell types . This ubiquitous role in transcriptional regulation makes BRD4 an important antibody target for studying gene expression mechanisms and epigenetic regulation.

How can I detect native BRD4 protein complexes using BRD4-B antibody?

Native BRD4 typically exists in large multiprotein complexes rather than as a monomeric protein. When fractionated by fast protein liquid chromatography (FPLC) with Superose 6 columns using a high salt extraction and size-exclusion approach, BRD4 immunoreactivity is detected in chromatographic fractions with a relative peak centered between 669 and 2,000 kDa . For optimal detection of these complexes, perform immunoprecipitation under non-denaturing conditions using BRD4-B antibody coupled to magnetic beads, followed by Western blotting with antibodies against suspected interacting partners such as components of the P-TEFb complex (CDK9, CCNT1) or the LSD1/NuRD complex (LSD1, CHD4, MTA2, MTA3, HDAC1, HDAC2, RBBP4/7) .

How can I distinguish between BRD4 hyperphosphorylation states using a BRD4-B antibody?

BRD4 hyperphosphorylation is associated with oncogenic activity in several cancer types. To analyze BRD4 phosphorylation states:

• Use Phos-tag gel analysis (5% PAGE gel containing 10 μM Phos-tag acrylamide AAL-107 and 40 μM MnCl₂) to separate phosphorylated forms

• Compare phosphorylation patterns between normal and cancer cells

• Treat samples with phosphatase inhibitors during extraction to preserve phosphorylation status

• Consider using phospho-specific antibodies alongside BRD4-B antibody

How can I investigate BRD4's interaction with the P-TEFb complex?

The interaction between BRD4 and the P-TEFb complex (CDK9 and cyclin T1) is crucial for understanding BRD4's role in transcriptional regulation. To investigate this interaction:

• Perform reciprocal co-immunoprecipitation experiments using BRD4-B antibody and antibodies against CDK9 or cyclin T1

• Compare the levels of interaction between normal cells and cancer cells, as cancer cells often show increased interaction

• Use recombinant proteins expressed in E. coli to verify direct interactions in vitro

• Consider competition assays with BRD4 C-terminal domain fragments to disrupt the interaction

Research has shown that the C-terminal fragment of BRD4 spanning amino acids 1134-1362 (C229) can effectively compete with full-length BRD4 for binding to P-TEFb, causing a dose-dependent reduction in P-TEFb co-immunoprecipitated with BRD4 antibody .

What are the methodological considerations for studying BRD4's dual function in transcriptional activation and repression?

BRD4 demonstrates a functional duality in super-enhancer organization of transcription activation and repression. To study this dual role:

• Perform chromatin immunoprecipitation sequencing (ChIP-seq) with BRD4-B antibody to map genome-wide binding sites

• Compare BRD4 binding with active (H3K27ac) and repressive (H3K27me3) histone marks

• Analyze BRD4 co-occupancy with components of the LSD1/NuRD repressive complex

• Use BET inhibitors (JQ1, CPI203) to disrupt BRD4 binding and measure effects on both activated and repressed genes

This approach can help distinguish between BRD4's activating role through P-TEFb and its repressive function through association with LSD1/NuRD complex .

What controls should I include when using BRD4-B antibody for immunoprecipitation studies?

For reliable immunoprecipitation studies with BRD4-B antibody:

• Include negative controls: IgG from the same species as the BRD4-B antibody

• Include positive controls: Immunoprecipitate known BRD4 interacting partners (CDK9, CCNT1)

• Verify BRD4 pulldown efficiency by Western blotting a small portion of the immunoprecipitate

• Validate novel interactions with reciprocal co-immunoprecipitation using antibodies against the interacting proteins

• Consider protein overexpression systems (FLAG-tagged BRD4) for improved specificity

Additionally, when analyzing immunoprecipitation results by Western blotting, use the Odyssey infrared scanner and appropriate secondary antibodies for quantitative analysis of binding interactions .

How do BET inhibitors affect BRD4 detection with BRD4-B antibody?

BET inhibitors like JQ1 and CPI203 bind to the bromodomains of BRD4 and may affect epitope recognition by certain antibodies. Consider the following:

• Pre-treatment with BET inhibitors can displace BRD4 from chromatin, potentially affecting subcellular localization

• Compare nuclear and cytoplasmic fractions when analyzing BRD4 levels after inhibitor treatment

• For immunofluorescence studies, optimize fixation conditions as inhibitor binding may alter conformation

• Use multiple antibodies recognizing different epitopes to confirm results

For comparative inhibitor assays, established protocols include the BRD4 α-screen assay, MYC cellular assay, and IL-6 release assay from THP-1 monocytic leukemia cells treated with inhibitors before LPS stimulation .

How can I design experiments to study BRD4's kinase activity using BRD4-B antibody?

Beyond its role as an epigenetic reader, BRD4 functions as an atypical kinase that phosphorylates Serine2 of the RNA polymerase II C-terminal domain (CTD). To study this kinase activity:

• Immunoprecipitate BRD4 with BRD4-B antibody from nuclear extracts

• Perform in-gel kinase assays with immunoprecipitated BRD4:

  • Run purified BRD4 on SDS-PAGE

  • Denature with 6M guanidine hydrochloride and renature

  • Incubate with kinase buffer containing γ-³²P ATP

  • Detect phosphorylated proteins by autoradiography

• Test BRD4 binding to Pol II CTD by immobilizing GST-CTD on beads and incubating with purified BRD4

• Analyze CTD phosphorylation by Western blotting with phospho-specific antibodies

This approach allows for distinguishing between BRD4's scaffolding role in recruiting P-TEFb and its direct kinase activity on the Pol II CTD .

What methodological approaches can be used to study BRD4 hyperphosphorylation in cancer?

BRD4 hyperphosphorylation is associated with cancer and may support its oncogenic activities. To study this phenomenon:

Research has shown that CDK9 in the P-TEFb complex functions as a major BRD4 kinase, and CDK9 inhibitors dramatically decrease BRD4 phosphorylation in vitro . This hyperphosphorylation may be a general mechanism supporting BRD4's oncogenic activities in various cancers .

How can I optimize co-immunoprecipitation protocols to detect weak or transient BRD4 interactions?

BRD4 participates in many protein-protein interactions, some of which may be weak or transient. To optimize detection:

• Use chemical crosslinking (DSP or formaldehyde at 0.1-0.5%) prior to cell lysis to stabilize transient interactions

• Adjust salt concentration in wash buffers (try 150-200 mM NaCl with 0.2% Nonidet P-40)

• Include phosphatase inhibitors to preserve phosphorylation-dependent interactions

• For weak interactions, reduce wash stringency and increase antibody concentration

• Consider native gel electrophoresis for complex intact analysis

When studying BRD4's interaction with the LSD1/NuRD complex, standard conditions include washing immunoprecipitates three times with 50 mM Tris pH 8.0, 200 mM NaCl, and 0.2% Nonidet P-40 .

What are the potential sources of variability in BRD4 detection across different cell lines?

Researchers may encounter variability in BRD4 detection across different cell lines. Key factors include:

• Expression level differences - BRD4 is expressed at variable levels across cell lines

• Phosphorylation status - Cancer cells often exhibit hyperphosphorylated BRD4

• Protein complex formation - BRD4 interaction partners may vary by cell type

• Nuclear localization - The proportion of chromatin-bound vs. free BRD4 varies

• Alternative splicing - Different BRD4 isoforms may be expressed

To address these variables, always include positive controls from cell lines with known BRD4 expression patterns, and consider analyzing both whole cell lysates and nuclear extracts to get a complete picture of BRD4 distribution and modification status.